Search

News & Events
Wal-yan researchers to join global respiratory congress in ViennaResearchers from the Wal-yan Respiratory Research Centre are proud to be part of this prestigious event, contributing their expertise to the Congress' outstanding scientific programme.

News & Events
Wal-yan respiratory researchers presented with prestigious awardsFour outstanding researchers from the Wal-yan Centre - Professor André Schultz, Professor Stephen Stick, Rebecca Watson and Michael Beaven - have been presented with prestigious awards in acknowledgement of their research aimed at improving the lives of children with respiratory illness.

Phage WA have a number of projects underway and these cover a broad range of phage research areas.

"Compassionate Use" treatments are novel treatments not widely available to everyone, but ones that holds great promise for potentially becoming a widely used treatment in the future.

News & Events
Raine Foundation support for researchers from The KidsCongratulations to six researchers from The Kids Research Institute Australia, who will use valuable support from the Raine Medical Research Foundation’s 2024 grant round to undertake projects focused on improving the health and wellbeing of babies, children and young people.

News & Events
Multi-million-dollar investment in child health to support vital researchFour The Kids Research Institute Australia researchers have received prestigious fellowships and four significant cohort studies led or co-led by The Kids have received key grants under two new funding programs supported by the State Government’s Future Health Research and Innovation (FHRI) Fund.

News & Events
Biobank funding supports valuable research resourcesFour The Kids Research Institute Australia-based biobanks which underpin a range of cancer, respiratory and early life research have received more than $450,000 in funding.

News & Events
World-first study shows increased atmospheric CO2 levels damage young lungsAustralian researchers who have conducted the first study looking at the direct health impacts of predicted carbon dioxide levels say the results are worrying and highlight the urgent need for more research into the issue.
Research
Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniaeThe increasing occurrence of hospital-associated infections, particularly bacteremia, caused by extensively drug-resistant (XDR) carbapenemase-producing colistin-resistant Klebsiella pneumoniae highlights a critical requirement to discover new therapeutic alternatives. Bacteriophages having host-specific bacteriolytic effects are promising alternatives for combating these pathogens.
Research
BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosisCystic fibrosis (CF) is a rare, inherited, life-limiting condition predominantly affecting the lungs, for which there is no cure. The disease is characterized by recurrent pulmonary exacerbations (PEx), which are thought to drive progressive lung damage. Management of these episodes is complex and generally involves multiple interventions targeting different aspects of disease. The emergence of innovative trials and use of Bayesian statistical methods has created renewed opportunities for studying heterogeneous populations in rare diseases.